Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026282 | 1.00 | KCNH2 (1.00) | KCNH2KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5024071 | 0.90 | KCNH2 (0.82) | KCNH2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5024011 | 0.89 | KCNH2 (0.80) | KCNH2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5023984 | 0.87 | KCNH2 (0.76) | KCNH2 | |
| SCHEMBL5024658 | 0.86 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5026271 | 0.86 | KCNH2 (0.75) | KCNH2KDM4EALDH1A1HTT | |
| SCHEMBL5027802 | 0.85 | KCNH2 (0.74) | KCNH2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5076819 | 0.85 | KCNH2 (0.77) | KCNH2KDM4EALDH1A1HTT | |
| SCHEMBL5017386 | 0.85 | KCNH2 (0.74) | KCNH2KDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL8302796 | 0.85 | KCNH2 (0.73) | KCNH2KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152568-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. | 2025-05-15 | — | — | US | claimed |
| EP-4475887-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | Aisa Pharma, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2024211216-A1 | CILNIDIPINE AND A P-GLYCOPROTEIN INHIBITOR FOR TREATING PAIN | AISA PHARMA, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2023150336-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | claimed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | claimed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | claimed |
| EP-4683634-A1 | TREATMENT OF SCLERODERMA | Aisa Pharma, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250152568-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | AISA PHARMA, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4523748-A2 | TREATMENT OF PAIN AND VASOCONSTRICTION | Aisa Pharma, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4475887-A1 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | Aisa Pharma, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240398771-A1 | TREATMENT OF SCLERODERMA AND RAYNAUD'S SYNDROME | AISA PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4114466-B1 | TREATMENT OF PAIN AND VASOCONSTRICTION | AISA PHARMA INC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2022115576-A2 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220168286-A1 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. | 2022-06-02 | — | — | US | disclosed |
| US-20090012095-A1 | HUMAN N-TYPE CALCIUM CHANNEL BLOCKERS | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012095-A1 | HUMAN N-TYPE CALCIUM CHANNEL BLOCKERS | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012095-A1 | HUMAN N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1G, CACNA1F | KCNH2 80/4885KDM4E 3959/4885ALDH1A1 4336/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | KCNH2 109/4885KDM4E 3858/4885ALDH1A1 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.